| Item Type | Name |
|
Academic Article
|
Adenoviral infections in hematopoietic stem cell transplantation.
|
|
Academic Article
|
Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications.
|
|
Academic Article
|
Improving T cell therapy for cancer.
|
|
Academic Article
|
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.
|
|
Academic Article
|
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
|
|
Academic Article
|
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.
|
|
Academic Article
|
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.
|
|
Academic Article
|
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
|
|
Academic Article
|
Adoptive immunotherapy for posttransplantation viral infections.
|
|
Academic Article
|
Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma.
|
|
Academic Article
|
Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.
|
|
Academic Article
|
T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients.
|
|
Academic Article
|
CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines.
|
|
Academic Article
|
Engineered T cells for pancreatic cancer treatment.
|
|
Academic Article
|
Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
|
|
Academic Article
|
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.
|
|
Academic Article
|
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.
|
|
Academic Article
|
Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells.
|
|
Academic Article
|
Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation.
|
|
Academic Article
|
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.
|
|
Academic Article
|
Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes.
|
|
Academic Article
|
Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation.
|
|
Academic Article
|
Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience.
|
|
Academic Article
|
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).
|
|
Academic Article
|
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.
|
|
Academic Article
|
Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.
|
|
Academic Article
|
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
|
|
Academic Article
|
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation.
|
|
Academic Article
|
PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.
|
|
Academic Article
|
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
|
|
Academic Article
|
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.
|
|
Academic Article
|
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.
|
|
Academic Article
|
T-cell therapy: a powerful tool for the management of viral infections and relapse post hematopoietic stem cell transplantation.
|
|
Academic Article
|
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
|
|
Academic Article
|
Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells.
|
|
Academic Article
|
Adenovirus as an emerging pathogen in immunocompromised patients.
|
|
Academic Article
|
Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12.
|
|
Academic Article
|
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.
|
|
Academic Article
|
Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale.
|
|
Academic Article
|
Cytotoxic T lymphocytes as immune-therapy in haematological practice.
|
|
Academic Article
|
Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.
|
|
Academic Article
|
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.
|
|
Academic Article
|
Absence of systemic immune response to adenovectors after intraocular administration to children with retinoblastoma.
|
|
Academic Article
|
T-cell therapy: the next generation.
|
|
Academic Article
|
Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.
|
|
Academic Article
|
Enhancing immune reconstitution: from bench to bedside.
|
|
Academic Article
|
Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.
|
|
Concept
|
Lymphocytes
|
|
Concept
|
T-Lymphocytes, Cytotoxic
|
|
Concept
|
Lymphocyte Activation
|
|
Concept
|
Lymphocyte Depletion
|
|
Concept
|
CD8-Positive T-Lymphocytes
|
|
Concept
|
Lymphocyte Count
|
|
Concept
|
CD4-Positive T-Lymphocytes
|
|
Concept
|
B-Lymphocytes
|
|
Concept
|
T-Lymphocyte Subsets
|
|
Concept
|
Epitopes, T-Lymphocyte
|
|
Concept
|
Lymphocytes, Tumor-Infiltrating
|
|
Concept
|
Lymphocyte Subsets
|
|
Concept
|
T-Lymphocytes
|
|
Concept
|
Lymphocyte Transfusion
|
|
Academic Article
|
Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.
|
|
Academic Article
|
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
|
|
Academic Article
|
Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.
|
|
Academic Article
|
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.
|
|
Academic Article
|
T-cell therapy for viral infections.
|
|
Academic Article
|
T lymphocytes targeting native receptors.
|
|
Academic Article
|
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.
|
|
Academic Article
|
Reversal of tumor immune inhibition using a chimeric cytokine receptor.
|
|
Academic Article
|
Systemic inflammatory response syndrome after administration of unmodified T lymphocytes.
|
|
Academic Article
|
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.
|
|
Academic Article
|
Antiviral T-cell therapy.
|
|
Academic Article
|
Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.
|
|
Academic Article
|
Engineered T cells for cancer treatment.
|
|
Academic Article
|
Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.
|
|
Academic Article
|
Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.
|
|
Academic Article
|
General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation.
|
|
Academic Article
|
Preventing stem cell transplantation-associated viral infections using T-cell therapy.
|
|
Academic Article
|
Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.
|
|
Academic Article
|
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
|
|
Academic Article
|
Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.
|
|
Academic Article
|
Characterizing the Cellular Immune Response to Parainfluenza Virus 3.
|
|
Academic Article
|
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
|
|
Academic Article
|
Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy.
|
|
Academic Article
|
Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus.
|
|
Academic Article
|
Dynamics of virus-specific T cell immunity in pediatric liver transplant recipients.
|
|
Academic Article
|
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.
|
|
Academic Article
|
Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients.
|
|
Academic Article
|
Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
|
|
Academic Article
|
Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.
|
|
Academic Article
|
Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections.
|
|
Academic Article
|
Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
|
|
Academic Article
|
Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia.
|
|
Academic Article
|
Identification of protective T-cell antigens for smallpox vaccines.
|
|
Academic Article
|
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.
|
|
Academic Article
|
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.
|
|
Academic Article
|
Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors.
|
|
Academic Article
|
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients.
|
|
Academic Article
|
Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2-Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients.
|
|
Academic Article
|
T cell immune profiling of respiratory syncytial virus for the development of a targeted immunotherapy.
|